Kenta Yokoi

Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib

Kenta Yokoi, Akira Kobayashi, Hiroaki Motoyama et al. · Oncology Reports · 2017 · 39 citations · Full text

Survival Pathway, Chemoprevention Strategy, Medicine +15

Synthesis and Anticancer Properties of Bis‐ and Mono(cationic peptide) Hybrids of Cyclometalated Iridium(III) Complexes: Effect of the Number of Peptide Units on Anticancer Activity

Jebiti Haribabu, Yuichi Tamura, Kenta Yokoi et al. · European Journal of Inorganic Chemistry · 2021 · 32 citations

Cationic Peptide, Engineering, Peptide Engineering +21

Amphiphilic Cationic Triscyclometalated Iridium(III) Complex–Peptide Hybrids Induce Paraptosis-like Cell Death of Cancer Cells via an Intracellular Ca²⁺-Dependent Pathway

Kenta Yokoi, Chandrasekar Balachandran, Masakazu Umezawa et al. · ACS Omega · 2020 · 27 citations · Full text

Induction of Paraptosis by Cyclometalated Iridium Complex-Peptide Hybrids and CGP37157 via a Mitochondrial Ca²⁺Overload Triggered by Membrane Fusion between Mitochondria and the Endoplasmic Reticulum

Kenta Yokoi, Kohei Yamaguchi, Masakazu Umezawa et al. · Biochemistry · 2022 · 26 citations · Full text

Cyclometalated Iridium(III) Complex–Cationic Peptide Hybrids Trigger Paraptosis in Cancer Cells via an Intracellular Ca2+ Overload from the Endoplasmic Reticulum and a Decrease in Mitochondrial Membrane Potential

Chandrasekar Balachandran, Kenta Yokoi, K Naito et al. · Molecules · 2021 · 25 citations · Full text